Neuropharmacology’s gendered blind spots: How psychedelic research reproduces systemic cognitive bias
Original framing: “Daily Briefing: Tiny doses of LSD seem to boost cognition” — Nature
The gendered exclusion in LSD trials mirrors the 1960s–70s, when women were systematically barred from psychedelic research under the pretext of 'protection' (e.g., FDA’s 1977 guidelines). Early studies like those at Harvard’s Psilocybin Project (1960s) used male subjects exclusively, yet the results were generalized to all humans—a pattern repeated today. The current study’s finding that LSD ‘works’ only in women inverts this history, revealing how structural bias creates artificial 'discoveries.' Meanwhile, the pharmaceutical industry’s push for 'psychedelic-assisted therapy' echoes the 1950s–60s, when LSD was marketed as a 'wonder drug' before being criminalized—a cycle of hype and suppression.
The LSD study’s gendered result is not a 'breakthrough' but a **revelation of what was always suppressed**: the pharmaceutical industry’s historical erasure of women’s bodies in research, the colonial extraction of Indigenous psychedelic knowledge, and the trickster-like inversion where 'progress' is just the universe correcting centuries of bias.
The framing obscures how psychedelics have been **both weaponized (MKUltra) and weaponized again (Big Pharma’s 'therapy' model)**, while the gendered data gap mirrors patterns from ADHD meds to antidepressants—where female-specific responses are treated as anomalies. Cross-culturally, the result aligns with Indigenous models where psychedelics serve **collective healing**, not individual 'enhancement,' yet these frameworks are absent from Western narratives. The solution lies in **decolonizing research** (Indigenous co-stewardship), **mandating gender-inclusive designs**, and using **trickster humor** to disrupt the solemnity of 'innovation' narratives. The real question is not *whether* LSD works, but *who gets to decide*—and whose knowledge was stolen to make that decision possible.